EU approves Illumina's plan to divest cancer test maker Grail
The EU's executive Commission approved Illumina's plan to unwind its completed acquisition of cancer diagnostic test maker Grail , it said in a statement on Friday.
Why Illumina Stock Zoomed Higher on Thursday
The gene-sequencing specialist might be able to complete a big-ticket asset buy after all. Its attempt to purchase Grail for $8 billion had been blocked by a European Union regulator.
EU court should back Illumina's appeal against EU review of Grail deal, court adviser says
Europe's top court should back U.S. gene sequencing company Illumina's appeal against the EU antitrust regulators' review of its $7.1 billion bid for cancer test maker Grail , an adviser to the cou...
Exclusive: Icahn drops Illumina board challenge threat, sources say
Activist investor Carl Icahn has dropped a threat to mount a new challenge to Illumina's board, sparing the U.S. gene sequencing company from its second proxy contest in as many years, according to...
Why Illumina Stock Mashed the Market on Monday
The biotech reported a pack of share purchases by a key insider. CEO Jacob Thaysen more than doubled his holdings.
Illumina (ILMN) Rides on NGS Portfolio Expansion Amid Macro Woe
In reproductive health, Illumina (ILMN) primarily focuses on driving noninvasive prenatal testing (NIPT) adoption globally.
Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down
Illumina (ILMN) Q4 revenues increase year over year, driven by NovaSeq X instrument and consumables sales.
Illumina, Inc. (ILMN) Q4 2023 Earnings Call Transcript
Illumina, Inc. (ILMN) Q4 2023 Earnings Call Transcript
Illumina (ILMN) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Illumina (ILMN) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics co...
Illumina forecasts flat 2024 sales as sluggish demand drags on
Illumina on Thursday forecast its annual core business revenue to be nearly flat compared to fiscal year 2023 as subdued demand for its genetic testing tools and diagnostics products extends into t...
Illumina (ILMN) Shares Down 1.2% Post Preliminary Q4 Results
Illumina's (ILMN) fourth-quarter 2023 results are likely to reflect the impacts of the adoption of its new generation of distributed liquid biopsy assay.
Why Illumina Rallied 36.6% in December
The beaten-down stock got a couple of analyst upgrades. Illumina also confirmed it would sell Grail, its controversial 2021 acquisition.
Illumina (ILMN) Extends Partnership to Advance Cancer Test
Illumina (ILMN) aims to work with other pharmaceutical industry leaders to enhance and expand the utility of its WGS MRD assay.
Illumina's story is too messy and uncertain right now, says Jim Cramer
'Mad Money' host Jim Cramer looks back at last year's worst performers on the Nasdaq.
Illumina Gives Up Fight With Regulators, Will Divest GRAIL
The saga over DNA sequencing firm Illumina Inc.'s (ILMN) controversial purchase of cancer diagnostic test maker GRAIL appears to be over.
Related Companies